MSMario Adriano dos Santos

Mario Adriano dos Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mario Adriano dos Santos has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impactos de sistemas eletrônicos de comunicação entre a atenção primária e a especializada: uma revisão integrativa

    by Marcella Cristina Halliday Muniz, Mario Adriano dos Santos, Brenda Carla Lima Araújo, Adicinéia Aparecida de Oliveira, Silvia de Magalhães Simões

    Plataformas de comunicação interprofissional têm se mostrado promissoras na articulação entre a atenção primária e a especializada. Este artigo buscou analisar os impactos na saúde resultantes do uso de sistemas eletrônicos de comunicação entre médicos generalistas e especialistas. Foi realizada uma revisão integrativa nas bases de dados BVS, PubMed e Scielo, e uma análise da literatura cinza na plataforma Google Scholar, sem filtro de tempo. Após aplicação dos critérios de inclusão e exclusão, foram selecionados 27 estudos. Estes foram publicados entre os anos de 2000 e 2020, foram em sua maioria estudos canadenses, e tiveram os sistemas eletrônicos desenvolvidos para múltiplas especialidades como predominantes. Por meio de abordagens variadas, os artigos destacaram redução nas taxas de encaminhamento para serviços de atenção especializada, economia de custos e melhoria da qualidade da assistência em saúde prestada pela atenção primária como impactos resultantes do uso das plataformas de comunicação interprofissional.


  • Open Access

    Telehealth in audiology: an integrative review

    by Thales Rafael Correia de Melo Lima, Larissa Menezes Santos, Marcella Cristina Halliday Muniz, Brenda Carla Lima Araújo, Mario Adriano dos Santos, Adicinéia Aparecida de Oliveira, Silvia de Magalhães Simões

    We performed an integrative review on the scientific literature about the use of telehealth in audiology care. Through high criteria search of published studies on the "Biblioteca Virtual em Saúde" - Virtual Health Library, PubMed, and Scientific Electronic Library Online databases, nine articles were selected. It was possible to verify that the use of telehealth in audiology is feasible and efficient, because it could promote audiological care for patients from away places. This process reaches more patients and communities by breaking down geographic barriers, and it offers a specific service not available with less cost and more quickly when compared with traditional speech therapy care.


  • Open Access

    Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment

    by Luana Heimfarth, Mario Adriano Dos Santos, José Augusto Barreto-Filho, André Barreto, Fabricio Macedo, Adriano Araújo, Paulo Martins-Filho, Marcus Scotti, Luciana Scotti, Lucindo Quintans-Júnior

    New coronavirus SARS-CoV-2 (COVID-19) has caused chaos in health care systems. Clinical manifestations of COVID-19 are variable, with a complex pathophysiology and as yet no specific treatment. It has been suggested that the renin-angiotensin-aldosterone system has a possible role in the severity of cases and the number of deaths. Our hypothesis is that drugs with inverse agonist effects to the angiotensin-1 receptor can be promising tools in the management of patients with COVID-19, possibly avoiding complications and the poor evolution in some cases. Any risk factors first need to be identified, and the most appropriate time to administer the drugs during the course of the infection also needs to be established. Several angiotensin receptor blockers (ARB) have a favorable profile and are important candidates for the treatment of COVID-19. In this review we discussed a set of compounds with favorable profile for COVID-19 treatment, including azilsartan, candesartan, eprosartan, EXP3174, olmesartan, telmisartan, and valsartan. They are effective as inverse agonists and could reduce the “cytokine storm” and reducing oxidative stress. As COVID-19 disease has several evolution patterns, the effectiveness of ARB therapy would be related to infection "timing", patient risk factors, previous use of ARBs, and the specific molecular effects of an ARB. However, controlled studies are needed to identify whether ARBs are beneficial in the treatment of patients with COVID-19.